The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.
Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. Type 1 diabetes is diagnosed by hyperglycemia often in combination with symptoms of weight loss, thirst, fatigue and frequent urination, sometimes with ketoacidosis. The clinical onset is preceded by an asymptomatic phase identified by serum multiple beta-cell autoantibodies. Neonates and infants who are at increased risk to develop multiple beta-cell autoantibodies and type 1 diabetes can now be identified using genetic markers. This provides opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.
Study Type
OBSERVATIONAL
Enrollment
1,000,000
Institut für Diabetesforschung, Helmholtz Zentrum München
Munich, Germany
RECRUITINGgreater than 10% risk for multiple beta-cell autoantibodies/type 1 diabetes
increased risk will be identified by risk scores derived from SNPs
Time frame: one-time testing before age 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.